Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies.
Treatment with neoadjuvant and adjuvant chemotherapy together with tumor resection changed treatment strategies in hepatoblastoma and led to prospective cooperative studies. The treatment strategies and results of three German liver tumor studies HB89, HB94 and HB99 are reviewed. Here we provide an overview of the treatment of this tumor in the years 1989 to 2008 in Germany. The treatment protocols, aim of studies and results are outlined. The overall-survival (OS), response to chemotherapy and toxicity are followed over this period of different treatment. The overall-survival improved over the last years with 75 % in HB89, 77 % in HB94 and 89 % HB99. Patients with potentially resectable tumors have a good prognosis although the treatment was reduced over the last years. Patients with non resectable tumors or lung metastases have also a better but still bad prognosis. The intensified treatment for these patients in Germany in the last years showed comparable results to international studies but no advantage.
Department of Pediatric Surgery, University of Munich, Lindwurmstr. 2, 80337 Muenchen, Germany. beate.haeberle@med.unimuenchen.de
Beate
B
Haeberle
Dietrich von
Dv
Schweinitz
D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005858:Germany; D018197:Hepatoblastoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*